A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Cavosonstat Administered Twice Daily Compared With Placebo for 24 Weeks in Adult Subjects With Chronic Obstructive Pulmonary Disease (COPD)

PHASE2UnknownINTERVENTIONAL

Enrollment

108

Participants

Timeline

Start Date

February 3, 2021

Primary Completion Date

December 31, 2021

Study Completion Date

April 30, 2022

Conditions

Chronic Obstructive Pulmonary Disease (COPD)

Interventions

OTHER

placebo

DRUG

Cavosonstat 5 mg

Cavosonstat (low dose)

DRUG

Cavosonstat 10 mg

Cavosonstat (medium dose)

DRUG

Cavosonstat 25 mg

Cavosonstat (high dose)